IBDEI3GL ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,58182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58182,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Mild Stage
 ;;^UTILITY(U,$J,358.3,58182,1,4,0)
 ;;=4^H40.33X1
 ;;^UTILITY(U,$J,358.3,58182,2)
 ;;=^5005861
 ;;^UTILITY(U,$J,358.3,58183,0)
 ;;=H40.33X2^^272^2901^126
 ;;^UTILITY(U,$J,358.3,58183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58183,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Moderate Stage
 ;;^UTILITY(U,$J,358.3,58183,1,4,0)
 ;;=4^H40.33X2
 ;;^UTILITY(U,$J,358.3,58183,2)
 ;;=^5005862
 ;;^UTILITY(U,$J,358.3,58184,0)
 ;;=H40.33X3^^272^2901^127
 ;;^UTILITY(U,$J,358.3,58184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58184,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Severe Stage
 ;;^UTILITY(U,$J,358.3,58184,1,4,0)
 ;;=4^H40.33X3
 ;;^UTILITY(U,$J,358.3,58184,2)
 ;;=^5005863
 ;;^UTILITY(U,$J,358.3,58185,0)
 ;;=H40.33X4^^272^2901^124
 ;;^UTILITY(U,$J,358.3,58185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58185,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,58185,1,4,0)
 ;;=4^H40.33X4
 ;;^UTILITY(U,$J,358.3,58185,2)
 ;;=^5005864
 ;;^UTILITY(U,$J,358.3,58186,0)
 ;;=H21.233^^272^2901^26
 ;;^UTILITY(U,$J,358.3,58186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58186,1,3,0)
 ;;=3^Degeneration of Iris,Bilateral
 ;;^UTILITY(U,$J,358.3,58186,1,4,0)
 ;;=4^H21.233
 ;;^UTILITY(U,$J,358.3,58186,2)
 ;;=^5005189
 ;;^UTILITY(U,$J,358.3,58187,0)
 ;;=H40.61X1^^272^2901^40
 ;;^UTILITY(U,$J,358.3,58187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58187,1,3,0)
 ;;=3^Drug-Induced Glaucoma,Right Eye,Mild Stage
 ;;^UTILITY(U,$J,358.3,58187,1,4,0)
 ;;=4^H40.61X1
 ;;^UTILITY(U,$J,358.3,58187,2)
 ;;=^5005907
 ;;^UTILITY(U,$J,358.3,58188,0)
 ;;=H40.013^^272^2901^59
 ;;^UTILITY(U,$J,358.3,58188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58188,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,58188,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,58188,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,58189,0)
 ;;=H40.012^^272^2901^60
 ;;^UTILITY(U,$J,358.3,58189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58189,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,58189,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,58189,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,58190,0)
 ;;=H40.011^^272^2901^61
 ;;^UTILITY(U,$J,358.3,58190,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58190,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,58190,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,58190,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,58191,0)
 ;;=H40.023^^272^2901^84
 ;;^UTILITY(U,$J,358.3,58191,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58191,1,3,0)
 ;;=3^Open-Angle w/ Borderline Findings,Hi Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,58191,1,4,0)
 ;;=4^H40.023
 ;;^UTILITY(U,$J,358.3,58191,2)
 ;;=^5005730
 ;;^UTILITY(U,$J,358.3,58192,0)
 ;;=H40.063^^272^2901^108
 ;;^UTILITY(U,$J,358.3,58192,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58192,1,3,0)
 ;;=3^Primary Angle-Closure w/o Glaucoma Damage,Bilateral
 ;;^UTILITY(U,$J,358.3,58192,1,4,0)
 ;;=4^H40.063
 ;;^UTILITY(U,$J,358.3,58192,2)
 ;;=^5005746
 ;;^UTILITY(U,$J,358.3,58193,0)
 ;;=H40.243^^272^2901^113
 ;;^UTILITY(U,$J,358.3,58193,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58193,1,3,0)
 ;;=3^Residual Stage Angle-Closure Glaucoma,Bilateral
 ;;^UTILITY(U,$J,358.3,58193,1,4,0)
 ;;=4^H40.243
 ;;^UTILITY(U,$J,358.3,58193,2)
 ;;=^5005845
 ;;^UTILITY(U,$J,358.3,58194,0)
 ;;=H40.043^^272^2901^121
 
--- Routine Detail   --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3GL   3952     printed  Sep 23, 2025@20:24:25                                                                                                                                                                                                    Page 2
IBDEI3GL  ; ; 19-NOV-2015
 +1       ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 +2        if 'DIFQR(358.3)
               QUIT 
           FOR I=1:2
               SET X=$TEXT(Q+I)
               if X=""
                   QUIT 
               SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
               SET X=$EXTRACT(X,4,999)
               if $ASCII(Y)=126
                   SET I=I+1
                   SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
               if $ASCII(Y)=61
                   SET Y=$EXTRACT(Y,2,999)
               XECUTE NO
              IF '$TEST
                   SET @X=Y
Q          QUIT 
 +1       ;;^UTILITY(U,$J,358.3,58182,1,0)
 +2       ;;=^358.31IA^4^2
 +3       ;;^UTILITY(U,$J,358.3,58182,1,3,0)
 +4       ;;=3^Traumatic Glaucoma,Bilateral,Mild Stage
 +5       ;;^UTILITY(U,$J,358.3,58182,1,4,0)
 +6       ;;=4^H40.33X1
 +7       ;;^UTILITY(U,$J,358.3,58182,2)
 +8       ;;=^5005861
 +9       ;;^UTILITY(U,$J,358.3,58183,0)
 +10      ;;=H40.33X2^^272^2901^126
 +11      ;;^UTILITY(U,$J,358.3,58183,1,0)
 +12      ;;=^358.31IA^4^2
 +13      ;;^UTILITY(U,$J,358.3,58183,1,3,0)
 +14      ;;=3^Traumatic Glaucoma,Bilateral,Moderate Stage
 +15      ;;^UTILITY(U,$J,358.3,58183,1,4,0)
 +16      ;;=4^H40.33X2
 +17      ;;^UTILITY(U,$J,358.3,58183,2)
 +18      ;;=^5005862
 +19      ;;^UTILITY(U,$J,358.3,58184,0)
 +20      ;;=H40.33X3^^272^2901^127
 +21      ;;^UTILITY(U,$J,358.3,58184,1,0)
 +22      ;;=^358.31IA^4^2
 +23      ;;^UTILITY(U,$J,358.3,58184,1,3,0)
 +24      ;;=3^Traumatic Glaucoma,Bilateral,Severe Stage
 +25      ;;^UTILITY(U,$J,358.3,58184,1,4,0)
 +26      ;;=4^H40.33X3
 +27      ;;^UTILITY(U,$J,358.3,58184,2)
 +28      ;;=^5005863
 +29      ;;^UTILITY(U,$J,358.3,58185,0)
 +30      ;;=H40.33X4^^272^2901^124
 +31      ;;^UTILITY(U,$J,358.3,58185,1,0)
 +32      ;;=^358.31IA^4^2
 +33      ;;^UTILITY(U,$J,358.3,58185,1,3,0)
 +34      ;;=3^Traumatic Glaucoma,Bilateral,Indeterminate Stage
 +35      ;;^UTILITY(U,$J,358.3,58185,1,4,0)
 +36      ;;=4^H40.33X4
 +37      ;;^UTILITY(U,$J,358.3,58185,2)
 +38      ;;=^5005864
 +39      ;;^UTILITY(U,$J,358.3,58186,0)
 +40      ;;=H21.233^^272^2901^26
 +41      ;;^UTILITY(U,$J,358.3,58186,1,0)
 +42      ;;=^358.31IA^4^2
 +43      ;;^UTILITY(U,$J,358.3,58186,1,3,0)
 +44      ;;=3^Degeneration of Iris,Bilateral
 +45      ;;^UTILITY(U,$J,358.3,58186,1,4,0)
 +46      ;;=4^H21.233
 +47      ;;^UTILITY(U,$J,358.3,58186,2)
 +48      ;;=^5005189
 +49      ;;^UTILITY(U,$J,358.3,58187,0)
 +50      ;;=H40.61X1^^272^2901^40
 +51      ;;^UTILITY(U,$J,358.3,58187,1,0)
 +52      ;;=^358.31IA^4^2
 +53      ;;^UTILITY(U,$J,358.3,58187,1,3,0)
 +54      ;;=3^Drug-Induced Glaucoma,Right Eye,Mild Stage
 +55      ;;^UTILITY(U,$J,358.3,58187,1,4,0)
 +56      ;;=4^H40.61X1
 +57      ;;^UTILITY(U,$J,358.3,58187,2)
 +58      ;;=^5005907
 +59      ;;^UTILITY(U,$J,358.3,58188,0)
 +60      ;;=H40.013^^272^2901^59
 +61      ;;^UTILITY(U,$J,358.3,58188,1,0)
 +62      ;;=^358.31IA^4^2
 +63      ;;^UTILITY(U,$J,358.3,58188,1,3,0)
 +64      ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Bilateral
 +65      ;;^UTILITY(U,$J,358.3,58188,1,4,0)
 +66      ;;=4^H40.013
 +67      ;;^UTILITY(U,$J,358.3,58188,2)
 +68      ;;=^5005726
 +69      ;;^UTILITY(U,$J,358.3,58189,0)
 +70      ;;=H40.012^^272^2901^60
 +71      ;;^UTILITY(U,$J,358.3,58189,1,0)
 +72      ;;=^358.31IA^4^2
 +73      ;;^UTILITY(U,$J,358.3,58189,1,3,0)
 +74      ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Left Eye
 +75      ;;^UTILITY(U,$J,358.3,58189,1,4,0)
 +76      ;;=4^H40.012
 +77      ;;^UTILITY(U,$J,358.3,58189,2)
 +78      ;;=^5005725
 +79      ;;^UTILITY(U,$J,358.3,58190,0)
 +80      ;;=H40.011^^272^2901^61
 +81      ;;^UTILITY(U,$J,358.3,58190,1,0)
 +82      ;;=^358.31IA^4^2
 +83      ;;^UTILITY(U,$J,358.3,58190,1,3,0)
 +84      ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Right Eye
 +85      ;;^UTILITY(U,$J,358.3,58190,1,4,0)
 +86      ;;=4^H40.011
 +87      ;;^UTILITY(U,$J,358.3,58190,2)
 +88      ;;=^5005724
 +89      ;;^UTILITY(U,$J,358.3,58191,0)
 +90      ;;=H40.023^^272^2901^84
 +91      ;;^UTILITY(U,$J,358.3,58191,1,0)
 +92      ;;=^358.31IA^4^2
 +93      ;;^UTILITY(U,$J,358.3,58191,1,3,0)
 +94      ;;=3^Open-Angle w/ Borderline Findings,Hi Risk,Bilateral
 +95      ;;^UTILITY(U,$J,358.3,58191,1,4,0)
 +96      ;;=4^H40.023
 +97      ;;^UTILITY(U,$J,358.3,58191,2)
 +98      ;;=^5005730
 +99      ;;^UTILITY(U,$J,358.3,58192,0)
 +100     ;;=H40.063^^272^2901^108
 +101     ;;^UTILITY(U,$J,358.3,58192,1,0)
 +102     ;;=^358.31IA^4^2
 +103     ;;^UTILITY(U,$J,358.3,58192,1,3,0)
 +104     ;;=3^Primary Angle-Closure w/o Glaucoma Damage,Bilateral
 +105     ;;^UTILITY(U,$J,358.3,58192,1,4,0)
 +106     ;;=4^H40.063
 +107     ;;^UTILITY(U,$J,358.3,58192,2)
 +108     ;;=^5005746
 +109     ;;^UTILITY(U,$J,358.3,58193,0)
 +110     ;;=H40.243^^272^2901^113
 +111     ;;^UTILITY(U,$J,358.3,58193,1,0)
 +112     ;;=^358.31IA^4^2
 +113     ;;^UTILITY(U,$J,358.3,58193,1,3,0)
 +114     ;;=3^Residual Stage Angle-Closure Glaucoma,Bilateral
 +115     ;;^UTILITY(U,$J,358.3,58193,1,4,0)
 +116     ;;=4^H40.243
 +117     ;;^UTILITY(U,$J,358.3,58193,2)
 +118     ;;=^5005845
 +119     ;;^UTILITY(U,$J,358.3,58194,0)
 +120     ;;=H40.043^^272^2901^121